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Iron-mediated oxidation of low-density lipoprotein has been implicated in the pathogenesis of vascu-
lar disorders such as atherosclerosis. The present investigations were performed to test whether hydro-
phobic fungal siderophores – hexadentate trihydroxamates desferricoprogen, desferrichrome, desfer-
rirubin, and desferrichrysin – might suppress heme-catalyzed LDL oxidation and the toxic effects of
heme-treated LDL on vascular endothelium. Indeed, two of these – desferricoprogen and desferri-
chrome – markedly increased the resistance of LDL to heme-catalyzed oxidation. In similar dose–
response fashion, these siderophores also inhibited the generation of LDL products cytotoxic to
human vascular endothelium. When iron-free fungal siderophores were added to LDL/heme oxidation
reactions, the product failed to induce heme oxygenase-1, a surrogate marker for the noncytocidal
effects of oxidized LDL (not in the case of desferrichrysin). Desferricoprogen also hindered the iron-
mediated peroxidation of lipids from human atherosclerotic soft plaques in vitro, and was taken up in
the gastrointestinal tract of rat. The absorbed siderophore was accumulated in the liver and was
secreted in its iron-complexed form in the feces and urine. The consumption of mold-ripened food
products such as aged cheeses and the introduction of functional foods and food additives rich in fun-
gal iron chelators in diets may lower the risk of cardiovascular diseases.
Keywords:Atherosclerosis / Functional food / Heme oxygenase / LDL oxidation / Siderophores /
Received: November 16, 2007; revised: January 24, 2008; accepted: January 24, 2008
1 Introduction
Reactive oxygen species and transition metals are thought
to be involved in the pathogenesis of numerous vascular
disorders such as atherosclerosis, vasculitis, reperfusion
injuries, and neonatal retinopathy of prematurity [1]. Envi-
ronmental factors greatly influence the onset and course of
these diseases as proved by epidemiological studies [2].
Important among these factors are infection, inflammation
and diet, all of which modulate oxygen and iron metabolism
[3–5]. Several epidemiological studies have suggested that
elevated tissue iron levels may increase the risk for athero-
sclerosis [6–8], although there are some contrasting views
[9, 10]. Intralesional accumulation of iron has been
observed in atherosclerosis [11, 12] and studies revealed
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that ferritin coupled to heme oxygenase-1 (HO-1) is highly
expressed in human atherosclerotic plaques [13, 14] possi-
bly reflecting a cellular response directly to heme- or iron
exposure or an indirect response to heme- or iron-generated
lipid peroxidation products [15, 16]. Infection generates
free radical stress through leukocyte activation and cyto-
kine production, which, while effective in killing patho-
gens, may cause secondary damage to the host.
The severity of inflammation-associated damage is
powerfully influenced by the presence of “loose” iron not
bound to iron-binding proteins such as transferrin and ferri-
tin [17, 18]. In many cases, chelators which suppress the
reactivity of iron have been found to ameliorate tissue dam-
age arising from inflammatory reactions [19, 20]. However,
the utility of the only clinically used high affinity chelator,
desferrioxamine B, is limited by its evanescence, potential
toxicity and lack of cell membrane penetration [21, 22].
Desferrioxamine was initially isolated from a bacterium
(Streptomyces pilosus), which uses the chelator as a means
for wresting iron from iron-poor environments [23–25].
Numerous other unicellular organisms also produce sidero-
phores but many of these have little promise for clinical
use. For example, a siderophore produced by Pseudomonas
aeruginosa, pyochelin, does not suppress iron-mediated
oxidation/reduction reactions and may even augment oxi-
dant cell injuries [26, 27].
Fungi also produce iron chelators, including hydroxa-
mates such as rhodotorulic acid, coprogens, ferrichromes,
and fusarinines [28]. Although the pharmacology of these
chelators is less well known than that of desferrioxamine B,
these compounds may be absorbed following the ingestion
of food containing fungi such as fungi-ripened food [29].
This raises the possibility that fungal siderophores may
influence the iron metabolism in humans and possibly mod-
ify the severity of iron-mediated pathological processes.
In many situations, the oxidation of PUFAs appears to be
a crucial event in oxidative cell damage. Recently it has
been shown that oxidation of LDL might occur not only in
the interstitial fluid but also within lysosomes of macro-
phages in the atherosclerotic lesion [30]. Such oxidation
can destroy the barrier function of membranes through oxi-
dation of unsaturated fatty acids in phospholipids and it has
been shown that prevention of fatty acid oxidation will, at
least in some experimental circumstances, prevent oxidant-
mediated cell death [1, 19, 31, 32]. The oxidation of PUFAs
almost always requires the presence of reactive transition
metals, notably iron. In the human body, one abundant and
potentially dangerous source of reactive iron is heme.
Heme is particularly hazardous because, being a hydropho-
bic iron “chelate”, it readily crosses cell membranes and
cells exposed to heme become extraordinarily sensitive to
oxidant damage [33]. Heme also promotes the conversion
of low-density lipoprotein to cytotoxic oxidized products
[34]. Cells respond to an influx of heme [35–38] and oxida-
tive stress [39–41] by inducing both HO-1 and ferritin. The
former cleaves the heme [42] and the latter represents a safe
storage site for the released iron [38]. The importance of
the heme–HO–ferritin system in human vascular disorders
was emphasized by the recent description of severe vascul-
opathy in the case of an HO-1 deficient child [43, 44].
However, the heme–HO–ferritin system may not be the
only effective way to deal with the challenges presented by
the combination of oxidants and iron sources. Because of
the above-mentioned drawbacks of the only clinically used
high affinity iron chelator, in the present study we have
investigated the possible beneficial (or deleterious) effects
of fungal siderophores in iron-catalyzed low-density lipo-
protein (LDL) peroxidation. We selected the hexadentate
trihydroxamates desferricoprogen, desferrichrome, desfer-
rirubin, and desferrichrysin (Fig. 1) for this study, which are
produced by Penicillium and Aspergillus species used fre-
quently in the food industry (e.g., P. roqueforti) or are
important in the spoilage of different food products (e.g.,
Aspergillus ochraceus). Our results show that these fungal
iron chelators, often present in the human diet, variably sup-
press heme-mediated oxidative modification of LDL, pre-
vent the formation of cytotoxic oxidized LDL and diminish
the homeostatic upregulation of HO-1 expression in human
vascular endothelial cells exposed to heme-treated LDL.
Moreover, one of the siderophores produced frequently by
Penicilium spp. – desferricoprogen – hindered consider-
ably the iron-mediated oxidation of the lipid cores of human
atheromas, and was absorbed in the gastrointestinal tract of
rat. We are speculating that the consumption of either tradi-
tional mold-ripened food or new-type functional food rich
in fungal hexadentate trihydroxamate siderophores may be
beneficial in the prevention of cardiovascular disorders like
atherosclerosis.
2 Materials andmethods
2.1 Purification of coprogen, ferrichrome, and
related compounds
Fungal hexadentate siderophores (Fig. 1) were purified
from culture fluids of Penicillium chrysogenum (coprogen,
ferrichrome), Neurospora crassa (coprogen) cultivated in
defined low-iron minimal media [45–47]. The purification
schemes included Amberlite XAD-2, Kieselgur G, and Bio-
Gel P-2 liquid chromatographies and preparative HPLC on
a Supelcosil-Si matrix [47, 48]. The purity of ferri-sidero-
phores was checked by HPLC using a C-18 RP column [49,
50], and pure ferri-siderophores were deferrated using
methanolic 8-hydroxyquinoline [51, 52]. Yields for desfer-
ricoprogen were 35 mg/L culture medium with P. chrysoge-
num and 66 mg/L culture medium with N. crassa. Ferri-
chrome, ferrichrysin and ferrirubin were in part a kind gift
of Dr. G. Winkelmann (University of Tbingen) or were
bought from Biophore Research Products (Tbingen, Ger-
many). The bacterial hexadentate siderophore desferriox-
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amine B, which was used as a control in the same experie-
ments, was purchased as Desferalm from Novartis (Basel,
Switzerland).
2.2 Isolation of low-density lipoprotein
LDL was isolated from plasma derived from EDTA (1 mg/
mL)-anticoagulated venous blood taken from healthy over-
night-fasted volunteers [53, 54]. Density of plasma was
adjusted to 1.3 g/mL with KBr, and a two-layer gradient
was made in a Quick-Seal polyallomer ultracentrifuge tube
(Beckman Instruments) by layering 0.9% NaCl on 10 mL
of density adjusted plasma, which was then centrifuged at
3020006g for 3 h at 48C (VTi 50.2 rotor, Beckman Instru-
ments, Brea, CA, USA). Purity of the LDL fraction was
checked by agarose gel electrophoresis. The LDL samples
were kept at 48C and protected from light, and the protein
content was determined by the BCA protein assay (Pierce,
Rockford, IL, USA).
2.3 Oxidative resistance of LDL
Heme-mediated oxidation of LDL was monitored by both
measuring conjugated diene formation and heme degrada-
tion spectrophotometrically at 234 and 405 nm, respec-
tively. Reaction mixtures contained LDL (200 mg/L pro-
tein), heme (5 lM), hydrogen peroxide (75 lM), and
HEPES buffer (10 mM, pH 7.4) [34, 53, 54]. When sidero-
phores were employed, we preincubated LDL samples with
them to allow their incorporation into the LDL. In heme-
catalyzed oxidation of LDL, heme degradation occurs in
concert with formation of lipid oxidation products includ-
ing conjugated dienes and lipid hydroperoxides. Thus,
heme degradation reflects the progress of lipid peroxida-
tion. The kinetics of heme disappearance was monitored at
405 nm in an automated microplate reader (model EL340,
Bio-Tek Instruments, Winooski, VT, USA). LDL oxidation
was monitored by the time (DT) required for the process to
achieve maximum velocity (Vmax) of heme degradation in
minutes. Reaction mixtures were supplemented as indicated
with desferri-siderophores at concentrations of 5, 10, and
25 lM.
2.4 Saturation of LDLwith coprogen and
desferricoprogen
The physical incorporation of both coprogen and desferri-
coprogen into LDL was demonstrated in vitro. Isolated
LDL was incubated with coprogen and desferricoprogen
within the concentration range of 10–250 lM for 2 h at
378C in a volume of 2.0 mL containing 1 mg of LDL pro-
tein. The samples were dialyzed exhaustively against phys-
iological saline (362 h), and one series of desferricopro-
gen-treated LDL samples were supplemented with FeCl3 in
a molar ratio of desferricoprogen/FeCl3 1:5. All samples
were freeze-dried and extracted with 1.0 mL of ice-cold
methanol/double-distilled water (1:2) by vigorous mixing
for 2 min. After centrifugation at 100006g for 5 min, the
supernatants were analyzed using both analytical HPLC
and TLC [47, 49, 50].
2.5 Endothelial cell isolation and culture
Human umbilical vein endothelial cells (HUVECs) were
removed from human umbilical veins by exposure to dis-
3
i 2008WILEY-VCH Verlag GmbH &Co. KGaA,Weinheim www.mnf-journal.com
i:/3b2/Jobs/Mnf/2008/Heft9/467.3d 28. 5. 2008
Figure 1. Chemical structure of coprogen, ferrichrome, ferri-
chrysin, and ferrirubin. Desferricoprogen belongs to the family
of linear trihydroxamates while desferrichrome, desferrichry-
sin, and desferrirubin are cyclic modified hexapeptides.
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pase and cultured in medium 199 containing 15% fetal calf
serum, penicillin (100 U/mL), streptomycin (100 U/mL),
and heparin (5 U/mL) supplemented with L-glutamine,
sodium pyruvate, and endothelial cell growth factor [55].
Endothelial cells were identified by cell morphology and by
the presence of vonWillebrand factor.
2.6 Endothelial cell cytotoxicity assay
Confluent endothelial cells grown in 24-well tissue culture
plates were washed three times with Hank's balanced salt
solution (HBSS), and then exposed to a reaction mixture
containing LDL (200 mg/L), heme (5 lM), H2O2 (75 lM)
with or without the addition of iron-free or iron-saturated
siderophores (20 lM). After an incubation period of 4 h,
the test solutions were replaced with 500 ll of 3-[4,5-dime-
thylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT)
(0.5 mg/mL) dissolved in HBSS, and endothelial cell
monolayers were incubated for another 6 h. The reduced
MTTwas measured spectrophotometrically at 570 nm after
the formazan was dissolved in 100 lL of 10% SDS and
500 lL of hot isopropanol containing 20 mMHCl.
2.7 Heme oxygenase enzyme activity assay
Heme oxygenase activity in endothelial cell microsomes
was measured by bilirubin generation [55]. The induction
of HO activity was determined in endothelial cells grown in
10 cm-diameter tissue culture dishes and treated with a
reaction mixture containing LDL (50 mg/L), heme
(1.25 lM), H2O2 (18.75 lM) with or without the addition of
iron-free or iron-saturated siderophores (5 lM) for 60 min
followed by an 8 h incubation with complete media alone.
Endothelial microsomes were incubated with hepatic cyto-
sol (2 mg), hemin (20 lmol/L), glucose-6-phosphate dehy-
drogenase (0.2 units), and NADPH (0.8 mmol/L). The
formed bilirubin was extracted with chloroform and D OD
of 464 and 530 nm was measured (extinction coefficient
40 M–1 N cm– 1). Heme oxygenase activity is expressed as
pmol bilirubin formed/mg cell protein/60 min.
2.8 Heme oxygenase-1mRNA analysis
HO-1 mRNA content was analyzed in confluent HUVECs
incubated with control medium or LDL test solutions as
described above for the measurement of enzyme activity.
Cellular RNA was isolated using RNAzol (TEL-TEST,
Friendswood, TX, USA), and 20 lg quantities of total RNA
were run on agarose gels and transferred to nylon mem-
brane. The 28S and 18S ribosomal RNAs, and equal loading
of samples were checked by ethidium bromide staining.
Alternatively, 2 lg quantities of total RNA were subjected
to dot blot analysis. After crosslinking to the nylon mem-
branes, RNAs were hybridized with biotin-labeled cDNA
for HO-1 (Bioprime DNA Labeling System, Life Technolo-
gies) [32], and the HO-1-active bands and dots were visual-
ized by a chemiluminescent detection system (Photogene
System 2.0, Life Technologies). Autoradiographs were
quantified by computer-assisted videodensitometry.
2.9 Effect of desferricoprogen on heme-mediated
oxidation of atherosclerotic plaques
Specimens of human atherosclerotic lesions were obtained
from aorta or its primary branches of deceased heart-beat-
ing donors for organ transplantation. Removal of tissue
samples from deceased heart-beating donors was approved
by the Scientific and Research Ethic Comity of Scientific
Council of Health of the Hungarian Government. Entire
vessels and complete lesions were removed during dona-
tion, washed with saline, and dried. Small pieces of col-
lected vessel samples were dispersed in phosphate buffer
containing heme (10 lM) and desferricoprogen (25 and
50 lM) and then incubated for 24 or 48 h at 378C. For the
measurement of thiobarbituric acid-reactive substances
(TBARs), 250 lL of reaction mixture was combined with
250 lL thiobarbituric acid reagent (0.375 g 2-thiobarbituric
acid, 2.08 mL cc. HCl, 15 mL 10% trichloroacetic acid and
distilled water adjusted to a final volume of 100 mL). After
incubating at 908C for 20 min, the samples were cooled to
room temperature and extracted with 250 lL n-buthanol.
The concentration of TBARs was determined spectrophoto-
metrically at 532 nm (extinction coefficient = 1.566105
M–1 N cm–1) and was expressed as nmol/(mg tissue).
2.10 Uptake, secretion, and tissue accumulation of
desferricoprogen and coprogen administered
orally or intravenously in rat
FLF1 hybrid rats (m = 150–350 g; fed on a normal chow
diet) were treated with either desferricoprogen or coprogen
intravenously through femoral vein at a concentration of
50 mg/(kg body mass) (cstock solution = 20 mg/mL, dissolved in
sterile filtered saline), or orally at a concentration of
100 mg/(kg body mass), through orogastric tube. Rats were
kept in separate cages with free access to water and food. A
selected group of animals were also given 0.5 mL 20%
ethanol or 0.5 mL olive oil immediately after the oral
administration of the siderophore to estimate the influence
of alcohol and lipids on the absorption of siderophores in
the gut. All the animal experiments were approved by the
Animal Care and Use Committee of the University of
Debrecen.
Urine and feces specimens were collected for 24 h inter-
vals on the first, second, third, and sixth days following
siderophore administration. Urine samples were frozen at
–808C and lyophilized meanwhile feces samples were
shaken in 40 mL aliquots of water for 30 min, were centri-
fuged (10006g, 15 min), and the supernatants were frozen
(–808C) and lyophilized.
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To map the accumulation of orally administered desferri-
coprogen and coprogen in different organs and tissues, a
separate group of experimental animals were sacrificed
after 4, 12, and 24 h siderophore treatments after taking
blood samples (2.0–2.5 mL), which were fractionated into
blood cells and plasma by centrifugation. The liver, spleen
and intestinal epithelium of the animals were excised,
weighed, frozen at –808C and freeze-dried.
To extract and quantify siderophore contents of the col-
lected specimens, all lyophilized samples were homogen-
ized with a glass rod, suspended in 20 mL aliquots of 50%
methanol and agitated vigorously on a test tube spinner for
1 min. After centrifugation, the ferri-siderophore contents
of the supernatants were analyzed by HPLC as described
above. In the case of the desferricoprogen treatments, the
supernatants were divided into two equal, approximately
10 mL aliquots, one of which was supplemented with FeCl3
(with six-fold molar equivalents of the administered sidero-
phore). The difference between the ferri-siderophore con-
tents of FeCl3-treated and nontreated samples was consid-
ered as the quantity of the iron-free uncomplexed fraction
of the siderophore accumulated in the analyzed tissues and
organs.
2.11 Statistical analysis
Unless otherwise indicated, data are presented as
means l SD. The Student's t-test was employed to test stat-
istical significance.
3 Results
3.1 In vitro studies demonstrating the beneficial
effects of fungal siderophores on heme-
mediated LDL-peroxidation
The peroxidation of isolated LDL was followed by the gen-
eration of conjugated dienes at 234 nm and by heme degra-
dation at 405 nm. Neither iron-free nor iron-saturated fun-
gal chelators induced LDL lipid peroxidation alone. How-
ever, in the presence of heme the iron-free siderophores
inhibited the formation of conjugated dienes (Fig. 2). As
shown on Fig. 2 heme and hydrogen peroxide-mediated
LDL oxidation – which was followed by conjugated diene
formation – was inhibited by desferricoprogen which pro-
longed the initiation phase of lipid peroxidation. In contrast,
under the same conditions iron-saturated coprogen had no
effect on the heme-mediated oxidative modification of
LDL. Importantly, ferricoprogen did not initiate oxidative
modification of LDL. Oxidative modification of LDL does
not occur when LDL is treated with ferri-siderophores and
H2O2 suggesting that ferri-siderophores can not provide cat-
alytically active iron to the reaction therefore we can say
that ferri-siderophores are inert in the presence of H2O2.
Simultaneous measurements of heme degradation (fol-
lowed at 405 nm) yielded similar results to that of we have
got by measuring conjugated diene formation.
As shown in Table 1, heme-catalyzed oxidation of LDL
was inhibited by desferricoprogen in a dose-dependent
manner. Pretreatment of LDL with 10 lM of desferricopro-
gen then challenged to heme and H2O2 prolonged the DT at
Vmax value from 57 l 1 to 109 l 1 min, resulting in a 91%
increase in the resistance of LDL against heme-catalyzed
oxidation. Similarly to heme degradation the formation of
conjugated dienes and the accumulation of TBARs were
inhibited in a dose-dependent fashion (data not shown).
Desferricoprogen at the concentration of 250 lM and above
completely inhibited the oxidative modification of LDL
over a period of 7 days. The inhibition of peroxidation by
desferricoprogen was compared to those of other iron-free
fungal hexadentate chelators and to that of the bacterial
hexadentate desferrioxamine B (Table 2). Interestingly, des-
ferrirubin and desferrichrysin, although structurally similar
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Figure 2. Kinetics of lipid peroxidation of LDL catalyzed by
heme. The standard reaction mixture contained LDL (200 lg/
mL protein), heme (5 lM), H2O2 (75 lM) and was also supple-
mented with 100 lM desferricoprogen or 100 lM coprogen as
required Formation of conjugated dienes were monitored at
234 nm. Symbols stand for: 9, native LDL alone; 0, LDL + he-
me + H2O2; H, LDL + coprogen + heme + H2O2; h, LDL + des-
ferricoprogen + heme + H2O2; g, LDL + coprogen + H2O2.
Table 1. Dose dependence of the protective effect of desferri-
coprogen on LDL against oxidative modification triggered by
heme-H2O2
Concentration of
desferricoprogen (lM)
DT at Vmaxa)
(min)
RelativeDT atVmaxa)
(% of control)
0 57 l 1 100
10 109 l 1 191 l 2
50 206 l 1 361 l 2
100 225 l 6 395 l 10
250 A240 A420
a) DT at Vmax values were calculated from three independent
experiments. The protective effects were significant (p a
0.001) for all the desferricoprogen concentrations tested.
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to desferrichrome (Fig. 1), were significantly less effective
in preventing LDL oxidation. In contrast, the DT at Vmax was
greatly prolonged by 20 lM concentrations of desferricopr-
ogen, desferrichrome, and desferrioxamine B.
The effectiveness of desferricoprogen in suppressing
heme-catalyzed LDL oxidation (Fig. 2, Tables 1 and 2) sug-
gested that this chelator might enter LDL. Indeed, as shown
in Fig. 3, incubation of LDL with coprogen or desferricopr-
ogen led to substantial amounts of LDL-associated chela-
tors. The incorporation of both forms into LDL was dose-
dependent and saturable. Incubating 200 lg/mL LDL pro-
tein and 250 lM coprogen (total coprogen content in the
reaction buffer was 500 nmol) for 2 h led to the incorpora-
tion of 50.1 and 43.0% of the added coprogen and desferri-
coprogen (251 and 215 nmol/mg LDL protein), respec-
tively.
These results raised the question of whether the attenua-
tion of LDL oxidation by fungal iron chelators might dimin-
ish the vascular endothelial cell cytotoxicity of treated
LDL. Oxidized LDL contains products of lipid peroxida-
tion, among them lipid hydroperoxides directly toxic to
endothelial cells. LDL at 200 lg/mL concentration was
incubated in a standard lipid peroxidation reaction mixture
containing 5 lM heme and 75 lM H2O2 in the presence or
absence of 20 lMconcentrations of iron-free fungal sidero-
phores. After exposing endothelial cell monolayers to the
reaction mixtures for 4 h, the cytotoxic effect was meas-
ured. In these experiments, 20 lM desferrioxamine B was
used as a positive control [34]. As expected, LDL treated
with heme and hydrogen peroxide was markedly cytotoxic
whereas iron-free siderophores hindered the generation of
cytotoxic LDL in a pattern quite similar to that observed in
the kinetic analysis of LDL lipid peroxidation (Table 2).
The protective effect exerted by desferrichrysin was signifi-
cant but less than those of the other chelators tested (Fig. 4).
We previously found that oxidized LDL at sublethal con-
centrations markedly induced the expression of HO-1 gene
and increased HO enzyme activity in vascular endothelial
cells in vitro [40]. As a further test of the effectiveness of
the anti-oxidant activities of fungal siderophores, LDL sol-
utions were oxidized by heme and H2O2 for 1 h in the stand-
ard reaction mixture supplemented with siderophores at a
final concentration of 20 lM and then diluted to a final
LDL concentration of 50 lg/mL. Endothelial cells treated
with native LDL exhibited low levels of HO-1 mRNA
expression and HO enzyme activity demonstrated by
Northern blot analysis (Figs. 5A and B, first lane and bar)
and bilirubin generation (Fig. 5D, first bar). Oxidized LDL
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Table 2. Relative increases in the DT at Vmax values due to the
Fe3+-squevenging effect of desferri-siderophores in heme-cat-
alyzed oxidative modification of LDL by H2O2
DT atVmaxa,b) (%) Concentration of desferri-siderophores
5 lM 10 lM 20 lM
Desferricoprogen 134.8 191.3 341.3
Desferrirubin 134.8 186.9 254.3
Desferrichrysin 104.3 119.6 139.1
Desferrichrome 152.2 191.3 302.2
Desferrioxamine B 136.9 200.0 386.9
a) DT at Vmax values were normalized with DT at Vmax meas-
ured in heme-H2O2 LDL modification systems with no side-
rophore supplementation.
b) A typical set of data is shown.
Figure 3. Saturation of LDL with desferricoprogen and copro-
gen in vitro. LDL was incubated with coprogen or desferricopr-
ogen in the presence or absence of iron as described in Sec-
tion 2. After removal of unincorporated siderophores by dialy-
sis, coprogen content of LDL was measured. Symbols repre-
sent coprogen treatment (h), desferricoprogen treatment + -
FeCl3 added (f), desferricoprogen treatment without extra iron
added (g), desferricoprogen content of LDL after desferricopr-
ogen treatment (difference between coprogen levels with and
without FeCl3 addition) (F).
Figure 4. Protective effects of desferri-siderophores on endo-
thelial cells exposed to oxidatively modified LDL. LDL (200 lg/
mL) was oxidized with heme (5 lM) and H2O2 (75 lM) in the
presence of desferricoprogen, desferrirubin, desferrichrysin,
desferrichrome or desferrioxamineB at the concentration of
20 lM. HUVECs were exposed to the reaction mixtures for
4 h, and then cell cytotoxicity was measured by MTT assay.
Figure represents means and SD values calculated from three
independent experiments.
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caused a A40-fold increase in HO-1 mRNA expression
(Figs. 5A and B, second lane and bar) together with a ten-
fold increase in enzyme activity in human vascular endothe-
lial cells (Fig. 5D, second bar). When LDL oxidation was
inhibited by 20 lM desferricoprogen, increases in HO-1
mRNA levels (Figs. 5A and B, third lane and bar) and HO
enzyme activities (Fig. 5D, third bar) were almost totally
prevented. In contrast, coprogen did not inhibit LDL oxida-
tion and did not prevent HO-1 induction in endothelial cells
exposed to the products of the reaction (Fig. 5, fourth lane
and bars). As shown in Fig. 6, among the iron-free sidero-
phores only desferrichrysin was unable to prevent the
induction of the HO-1 gene (dot B4) in agreement with its
relatively weak protective effect against heme-mediated
LDL lipid peroxidation. The other fungal siderophores
together with the positive control desferrioxamine B effi-
ciently inhibited both the oxidation of LDL and the induc-
tion of HO-1 (dots B1–3, B5). Not surprisingly, iron-com-
plexed siderophores did not prevent the induction of HO-1
gene (dots C1–5), in agreement with their lack of effect on
LDL-oxidation. Importantly, when LDL was pretreated
with iron-complexed siderophores and H2O2 for 1 h in the
absence of heme and then incubated with endothelial cell
monolayers for 8 h at sublethal concentration neither HO-1
gene induction (Fig. 6, dots D1–5) nor increase in enzyme
activity (Fig. 5, fifth lane and bars) was observed.
3.2 The fungal siderophore desferricoprogen
prevents peroxidation of lipids from
atherosclerotic soft plaques
As previously described [34, 55], oxidative modification of
LDL is a key event in the development of atherosclerotic
lesions, and lipid cores of the atheromas are as sensitive for
oxidative modifications as LDL. Heme-mediated oxidation
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Figure 5. Correlation between intracellular HO-1 mRNA levels
and specific HO activities. LDL (200 lg/mL) was treated with
heme (5 lM) and H2O2 (75 lM) supplemented with 20 lM des-
ferricoprogen or coprogen as indicated, or LDL was treated
with coprogen and H2O2. After a 2 h pre-incubation, samples
were diluted four times, and HUVECs were treated with the
reaction mixtures. Heme oxygenase-1 mRNA levels were
determined by Northern blot (A), and mRNA concentrations
were quantified by videodensitometry (B). Panel C shows ethi-
dium bromide staining of the gel to prove equal loading of the
samples. HO-1 activity (D) was measured by bilirubin genera-
tion as described in Section 2. Specific HO-1 activities are
shown as means l SD calculated from three independent
experiments.
Figure 6. Dot blot analysis of the changes in the gene expres-
sion levels of HO-1 in the presence of desferri- and ferri-side-
rophores. A(4–5): positive control, upregulation of HO-1 after
LDL + heme + H2O2-treatment of endothelial cells. B(1–5):
protection of HUVECs with 20 lM desferrioxamine B, desferri-
coprogen, desferrirubin, desferrichrysin, and desferrichrome.
C (1–5): supplementation of reaction mixtures with 20 lM
iron-saturated ferrioxamine, coprogen, ferrirubin, ferrichrysin,
and ferrichrome. D (1–5) Treatment of HUVECs with
LDL + ferri-siderophore + H2O2 mixtures without any heme.
Siderophore– iron complexes were the same as in row C.
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of lipids originated from atherosclerotic soft plaques takes
place after about 12–18 h, which time was increased dose
dependently by desferricoprogen up to 24 h (Fig. 7A). In
contrast, desferricoprogen had no protective effect when
oxidation last longer (48 h; Fig. 7B).
3.3 Uptake, accumulation, and secretion of
desferricoprogen and coprogen in rat
Considering uptake and accumulation of orally adminis-
tered desferricoprogen and coprogen, substantial quantities
of siderophore appeared in the liver 1 day after administra-
tion (8.5–9.5%; Figs. 8 and 9) meanwhile there was no
detectable amount of siderophore in the spleen. Interest-
ingly, when desferri- and ferri-siderophores were dosed
intravenously small amounts (0.05–0.07%) of siderophore
was detected in the spleen. Approximately 0.1% of the
orally administered siderophore remained in the intestinal
epithelium (Fig. 8) while there was no detectable sidero-
phore in the intestinal epithelial cells when desferricopro-
gen was added intravenously. No coprogen was detected in
blood cells separated from any blood specimen and the
serum concentration of the siderophore was always about
0.01 mg/mL (12 lmol/L in coprogen equivalents), which
was around the LOD of the HPLC procedure used. Impor-
tantly, 3.5 times more (21.5% vs. 6.2%) siderophore was
detected in feces and 2.6 times more (0.90% vs. 0.34%)
siderophore was secreted in urine when coprogen was
added in iron-complexed form (Fig. 8). Surprisingly,
approximately 84% of orally administered desferricopro-
gen and 74% of orally administered coprogen were neither
secreted into the feces and urine nor accumulated in the
organs and tissues studied 1 day after dosage. Secretion of
orally administered siderophores was followed up to 6 day
after dosage but the recorded quantities were always low
(f1%; data not shown). Coprogen was secreted into both
feces and urine exclusively in its iron-complexed form
independently of that ferri- or desferri-siderophore was
administered.
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Figure 7. Desferricoprogen protects atherosclerotic plaques
against heme-mediated oxidation. Atherosclerotic plaques
were incubated with heme in the presence or absence of des-
fericoprogen, and concentration of TBARs were measured.
Significant (p a 0.1%) protective effect was observed at 50 lM
desferri-siderophore concentration even after 24 h incubation
at in the presence of heme (A), but a prolonged (48 h) heme-
mediated oxidation eliminated this effect (B). Means l SDs cal-
culated from five independent experiments are presented.
Figure 8. Distribution of orally administered desferricoprogen
(A) and coprogen (B) between feces, urine, liver and intestinal
epithelium 1 day after dosage. Each animal was dosed with
100 mg/(kg body mass) siderophore. The data presented here
are means l SDs calculated from five independent experi-
ments and stand for mean total (desferri + ferri) siderophore
contents.
Mol. Nutr. Food Res. 2008, 52, 000–000
The hepatic accumulations of desferricoprogen and its
iron complex were studied in more details after both intra-
venous and oral applications. As shown in Fig. 9, about
14% (1.7% in desferri form) of intravenously added sidero-
phore localized in the liver within 5 min after administra-
tion and this amount increased further to 21–34% (7.2–
9.1% were not complexed with iron) 30 min–1 h post-
administration. During oral application, the coprogen con-
tent of the liver increased steadily and reached 8.6% (5.5%
in desferri form) of total administered coprogen 1 day after
dosage in this set of experiments (Fig. 9).
Co-administration of ethanol or olive oil did not affect
the accumulation of either desferricoprogen or coprogen in
the liver (Fig. 10). Secretion of siderophores in either feces
or urine as well as the low siderophore contents of intestinal
epithelium and spleen remained unaffected by ethanol and
oil (data not shown).
4 Discussion
In many experimental and clinical situations, it has been
shown that suppression of iron-catalyzed oxidation reac-
tions can have significant protective effects [1, 56, 57]. For
example, oxidation of LDL particles by free iron released
during the oxidative degradation of heme inside the hydro-
phobic domains of lipoprotein has been implicated in vas-
cular endothelial cell damage [32, 34, 58] and the bacterial
Fe3+-chelator desferrioxamine B has been found to effec-
tively inhibit such LDL oxidation. Li et al. [59] have dem-
onstrated that oxLDL-induced damage of macrophages is
associated with iron-mediated intralysosomal oxidative
reactions, leading to lysosomal rupture and subsequent
apoptosis, that can be prevented by the iron-chelator, des-
ferrioxamine. More recently, Minqin et al. [57] demon-
strated that desferrioxamine B inhibited atherosclerotic
lesion formation in rabbits on cholesterol-rich diet, and
reduced iron content of plaques. Importantly, iron chelation
improved endothelial function in patients with coronary
artery disease [22].
Unfortunately, desferrioxamine B has some serious
drawbacks in vivo: it has to be administered intravenously
[60], does not last very long in the circulation [20] and can
have serious side effects [61]. The present investigations
were carried out to estimate the potential of several fungal
siderophores to similarly suppress heme/iron-driven oxida-
tion reactions and cytotoxicity and to study their absorption
in the gastrointestinal tract. The results may have additional
interest inasmuch as fungi which make these siderophores
are used in making processed foods and exist as contami-
nants on commonly eaten foodstuffs [29].
All of the four fungal iron chelators tested here inhibited
heme-catalyzed oxidation of LDL and attenuated damage
to vascular endothelium caused by products of this LDL
oxidation. In contrast, iron-saturated siderophores failed to
provide cytoprotection against lipoprotein-mediated oxida-
tive injury. Furthermore, we demonstrated that upregulation
of redox sensitive HO-1 in response to oxidative stress was
also blunted. Interestingly, a significant difference was
observed in the extent of the inhibitory effects of the chela-
tors with desferricoprogen exhibiting the strongest inhibi-
tory potential in all of the three experiments (Table 2, Figs.
4–6). It is noteworthy that the weaker protective effect of
desferrichrysin and, at least in part that of desferrirubin
(Table 2), cannot be explained simply by differences in
iron-chelate stability because the stability constants of tri-
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Figure 9. Accumulation of coprogen in the liver after intrave-
nous (A) and oral (B) administrations of desferricoprogen. All
experimental animals were treated with 50 (intravenous) or
100 (oral) mg/(kg body mass) desferri-siderophore. The data
presented here are typical datasets.
Figure 10. Effect of ethanol and olive oil on the accumulation
of orally administered desferricoprogen and coprogen in the
liver of rats. Experimental animals were dosed with 100 mg/
(kg body mass) siderophore in each case. The data presented
here are means l SDs calculated from five independent
experiments and represent mean total (desferri + ferri) sidero-
phore contents recorded 24 h post-administration.
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hydroxamate– iron complexes are 30–31 (log b110 values
for the reactions of L3 – + Feaq3+ ﬁ FeL) independent of the
side-chains [24].
In heme-mediated peroxidation of LDL, heme is buried
in the lipoprotein surface monolayer with the carboxyl
groups in contact with positive regions of the protein and
the solvent [62]. Hence, the primary site for heme degrada-
tion, iron release and lipid peroxidation is the surface
monolayer itself [62, 63]. The iron-scavenging capability of
the siderophores tested may therefore be connected to their
partition coefficient and orientation within the surface
monolayer. The 2-hydroxymethyl moieties in the chemical
structures of ferrirubin and ferrichrysin (Fig. 1) may be dis-
advantageous for effective inhibition of iron-catalyzed lipid
peroxidation (Table 2). However, further studies are needed
to elucidate if satisfactory incorporation or proper orienta-
tion in the surface monolayer is disturbed in the case of fer-
rirubin and ferrichrysin. Importantly, coprogen was proven
to incorporate into LDL particles in its desferri-form (Fig.
3). This implies that free, redox-active iron, released during
oxidative reactions between heme, LDL, and H2O2, may be
captured in situ by desferricoprogen.
Ferri-siderophores were completely inert in all the LDL
modification and endothelial cell cytotoxicity experiments
(Figs. 2, 4–6), which is in good accordance with the low
redox potentials of Fe3+– trihydroxamate siderophore com-
plexes (E1/2 = –0.400–0.468 V) in aqueous solutions [24].
They also did not alter endothelial HO-1 expression,
although using coprogen, the incorporation of the chelator
into LDL particles is equivalent to that of desferricoprogen
(Fig. 3). When LDL was treated by coprogen in the pres-
ence of heme, LDL oxidation progressed, and the HO-1
gene was induced. In the absence of heme, the inclusion of
coprogen into the reaction mixtures did not generate LDL
oxidation, and did not result in HO-1 induction either. This
means that, similar to the bacterial desferrioxamine B, iron
ions buried in fungal hexadentate trihydroxamates are not
“redox-active” unlike the tridentate P. aeruginosa sidero-
phore pyochelin [26, 27]. Two of the tested four sidero-
phores, coprogen, and ferrichrome – both produced by
cheese-ripening Penicillium spp. – were approximately as
powerful as desferrioxamine B in preventing heme-cata-
lyzed LDL peroxidation and preventing the accumulation
of cytotoxic LDL oxidation products. Both fungal sidero-
phores may be a viable option to desferrioxamine B for the
in vivo suppression of iron-catalyzed oxidation reactions
and, perhaps, prevention of oxidant damage to tissues.
Catalytic iron – which can be derived from macrophages
by exocytosis [64] – plays a role in the severity of athero-
sclerosis [65] via oxidation of the lipid cores of atheromas
[34, 55, 65]. Desferricoprogen hindered considerably the
heme-mediated oxidation of human atherosclerotic soft pla-
que lipids although this effect was temporary (Fig. 7). It is
worth noting that desferrioxamine B only had a significant
effect on atherosclerotic lesion development and lesion iron
content in cholesterol-fed rabbits when the administration
of siderophore was extended to 12 wk [57]. The contribu-
tion of iron to the initiation and development of atheroscle-
rosis can be controlled only by long-term application of
iron-removing agents [57].
Our findings may have one further implication. To the
extent that these fungal siderophores may be absorbed by
the gastrointestinal tract, the possibility exists that diets rich
in fungal siderophores may provide protection against in
vivo lipid peroxidation, and atherogenesis. According to
our measurements, the coprogen content of P. roqueforti-
processed cheese can be as high as 38 mg/kg, A30% of
which is in the desferri-form.
The distribution of orally administered desferricoprogen
and coprogen in organs and feces and urine in the rat clearly
indicated that both the iron-complexed and the iron-free
forms of the siderophore was taken up in the gastrointesti-
nal tract and was accumulated primarily in the liver (Fig. 8).
Although the uptake and accumulation of desferricoprogen
was coupled to complexation of iron and coprogen was
only secreted in its ferri-form about 64% of liver-bound
siderophore was uncomplexed after 1 day of administration
(Fig. 9). When dosed intravenously, 21–34% of the admin-
istered desferricoprogen appeared in the liver 0.5–1.0 h
post-administration but the ratio of the iron-uncomplexed
form was considerably less, 27–34% of total absorbed side-
rophore (Fig. 9). Orally administered desferricoprogen was
eliminated from the body at a much lower rate than copro-
gen (Fig. 8) and similar observations were made during
intravenous administrations (data not shown). Hence, des-
ferricoprogen was retained meanwhile coprogen was
secreted more effectively than their iron-complexed and
iron-uncomplexed counterparts, respectively, influencing
negatively the body iron status. Although the total amount
of siderophore detected in blood was negligible in compari-
son to those found in liver or spleen the serum concentration
of coprogen was about 0.01 mg/mL (12 lmol/L), about one
third of the total serum iron concentration recorded in rats
(35.67 l 5.46 lmol/L) [66] and was comparable to that pub-
lished for humans (18.2 l 5.4 lmol/L) [67]. Frequent blood
donation lowering body iron may protect against acceler-
ated atherosclerosis [67, 68] but the hypothesized deleteri-
ous effects of dietary iron uptake and body iron stores on
the atherosclerotic process have been questioned most
recently [69, 70]. Therefore, the beneficial effects of dietary
siderophore uptake on the vascular system is expected to
come primarily from scavenging heme-released, biologi-
cally active free iron in the serum and LDL particles (Fig.
3) and extracting iron from atherosclerotic plaques (Fig. 7)
[34, 55, 58, 65] and not from the overall reduction of iron
stores [69, 70].
It is important to note that huge quantities of orally
administered desferricoprogen (84%) and coprogen (74%)
did not appear in either feces or urine and were not localized
in the tested organs either (Figs. 8 and 9). This may indicate
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(i) chemical and microbial degradation of the compounds
in the gastrointestinal tract, (ii) accumulation and storage of
siderophores in organs other than liver, spleen and intestinal
epithelium, or (iii) fast degradation of the chelator and/or
its iron-chelate in the liver. All three options will be taken
into consideration in forthcoming physiological and phar-
macokinetic investigations but at least one not-yet-identi-
fied coprogen derivative with HPLC retention time shorter
than that of coprogen has been detected in liver under both
oral and intravenous administrations of either desferricopr-
ogen or coprogen (data not shown). As the chemical compo-
sition and molar extinction coefficient of this siderophore
derivative has remained yet to be elucidated its concentra-
tion, which increased steadily in time, could not be esti-
mated. Important to know that this metabolite was not
dimerumic acid, a tetra-dentate iron-chelator, which is
formed by hydrolysis of the ester bond of coprogen (Figs. 1
and 11) [50, 71], and it also appeared in feces specimens in
various concentrations.
Although no information has been available thus far on
the gastrointestinal absorption and bioavailability [72] of
coprogen-type and ferrichrome-type siderophores in
humans hexadentates were considered in general as orally
inactive chelators [73]. This false conclusion arose from the
poor uptake of desferrioxamine B (Fig. 11) in the gastroin-
testinal tract [74]. Nevertheless, this bacterial hexadentate
trihydroxamate possesses a positively charged free amino
group (pK = 10.84; Fig. 7) [75] at physiologically relevant
pH values, which may influence profoundly its migration
through biological membranes [76]. Taking into considera-
tion the relatively high acidic dissociation constants of the
hydroxamate groups of desferrioxamine B (pK1 = 8.30,
pK2 = 9.00, pK3 = 9.46) we can establish that this sidero-
phore is a cation, i. e., an electrolyte, under physiological
conditions including the intestinal lumen.
Unlike desferrioxamine B, desferricoprogen with acidic
dissociation constants of pK1 = 8.00, pK2 = 9.00, and pK3 =
9.84 [77] is an uncharged nonelectrolyte under physiologi-
cal conditions (Fig. 11). Therefore, desferricoprogen pos-
sesses a more hydrophobic character, which was demon-
strated by its effective incorporation into LDL particles
(Fig. 3), and which may facilitate its migration across bio-
logical membranes too, including those of the epithelium of
the gastrointestinal tract. Considering the very different
physico-chemical characteristics of desferrioxiamine B and
coprogen it is now understandable why fungal nonelectro-
lyte hexadentate chelators are orally available. Of course,
the elucidation of the mechanism of the unexpected uptake
of desferricoprogen and coprogen in the gut needs further
studies.
It is worth noting that rhodotorulic acid, a tetradentate
dihydroxamate, which is structurally related to the copro-
gen family (Fig. 11), increased moderately urinary iron
excretion (up to 50–200 lg/kg/day) in iron-overloaded rats
when it was administered orally [78]. This observation also
indicated that there was some limited absorption of rhodo-
torulic acid in the gastrointestinal tract, which, of course,
was not satisfactory for a potential iron-chelating drug for
oral application [78].
Finally, in the particular case of LDL oxidation and athe-
rogenesis, the mind wonders to the famous “French para-
dox” wherein people who eat high lipid (often cheese-rich)
diets and drink wine are protected against atherogenesis.
This has been explained with the possible anti-oxidant
effects of wine, especially, red wine. But hold on – maybe
it is the cheese! The authors propose that traditional mold-
ripened foods as well as the introduction of new-type func-
tional foods and food additives rich in hexadentate trihy-
droxamate fungal siderophores might give us a new and
powerful tool in preventing vascular diseases such as athe-
rosclerosis.
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